Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05251220
Other study ID # 29.10?14
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1, 2018
Est. completion date December 24, 2020

Study information

Verified date February 2022
Source 1st Federal Budgetary Healthcare Institution Volga District Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Study objective: To evaluate the efficacy and safety of the Magic Max neodymium laser in the medical treatment of women with symptoms of genitourinary syndrome of menopausal, vulvar lichen sclerosus and pelvic floor muscle reduction.


Description:

Study objective: To evaluate the efficacy and safety of the Magic Max neodymium laser in the medical treatment of women with symptoms of genitourinary syndrome of menopausal, vulvar lichen sclerosus and pelvic floor muscle reduction. Materials and methods: 60 patients with diseases of the urogenital tract were enrolled into the study; they were treated with a neodymium (ND) laser: three 20-minute sessions every 28 ± 2 days. Efficacy was assessed by means of the Female Sexual Function Index (FSFI), ICIQ-SF, PISQ-12, SF36 survey forms, and a questionnaire to identify urinary disorders at the following time points: before treatment, one month after each session and 6 months after the last procedure.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date December 24, 2020
Est. primary completion date December 24, 2020
Accepts healthy volunteers No
Gender Female
Age group 29 Years to 72 Years
Eligibility Inclusion Criteria: - diseases of the urogenital tract - symptoms of genitourinary menopausal syndrome, - vulvar lichen sclerosus - pelvic floor muscle reduction Exclusion criteria: - pregnancy - oncological diseases

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Russian Federation Federal Budgetary Healthcare Institution "Volga District Medical Center" of the Federal Medical and Biological Agency Nizhny Novgorod Russia,Nighegorodskaya Oblast'

Sponsors (1)

Lead Sponsor Collaborator
1st Federal Budgetary Healthcare Institution Volga District Medical Center

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in dyspareunia (discomfort during sexual intercourse) from baseline Efficacy was assessed by means of the Female Sexual Function Index (FSFI)- a self-controlled questionnaire survey, including 19 items,allows you to evaluate the features of desire,arousal,arousal,orgasm,achieving sexual satisfaction,and the presence of dyspareunia.With the help of this questionnaire,it is possible to conduct a differential assessment of clinical manifestations of sexual disorders.5 points-the highest score of the result,1 point- the lowest score of the result. Questioning was conducted at the following time points: before laser treatment, one month after each laser treatment session, and 6 months after the last procedure.
Other Change in frequency of sexual activity sensations during sexual intercourse (sensitivity and arousal) from baseline Efficacy was assessed by means of the Female Sexual Function Index (FSFI)- a self-controlled questionnaire survey, including 19 items,allows you to evaluate the features of desire,arousal,arousal,orgasm,achieving sexual satisfaction,and the presence of dyspareunia.With the help of this questionnaire,it is possible to conduct a differential assessment of clinical manifestations of sexual disorders.5 points-the highest score of the result,1 point- the lowest score of the result. Questioning was conducted at the following time points: before laser treatment, one month after each laser treatment session, and 6 months after the last procedure.
Other Change in satisfaction with sex life from baseline Efficacy was assessed by means of the Female Sexual Function Index (FSFI)- a self-controlled questionnaire survey, including 19 items,allows you to evaluate the features of desire,arousal,arousal,orgasm,achieving sexual satisfaction,and the presence of dyspareunia.With the help of this questionnaire,it is possible to conduct a differential assessment of clinical manifestations of sexual disorders.5 points-the highest score of the result,1 point- the lowest score of the result. Questioning was conducted at the following time points: before laser treatment, one month after each laser treatment session, and 6 months after the last procedure.
Other Change in frequency of orgasms during sexual intercourse from baseline Efficacy was assessed by means of the Female Sexual Function Index (FSFI)- a self-controlled questionnaire survey, including 19 items,allows you to evaluate the features of desire,arousal,arousal,orgasm,achieving sexual satisfaction,and the presence of dyspareunia.With the help of this questionnaire,it is possible to conduct a differential assessment of clinical manifestations of sexual disorders.5 points-the highest score of the result,1 point- the lowest score of the result. Questioning was conducted at the following time points: before laser treatment, one month after each laser treatment session, and 6 months after the last procedure.
Other Change in general health condition from baseline Efficacy was assessed by SF36 quality of life survey form means of the this is a non-specific questionnaire for assessing the patient's quality of life.When 1 point-is the highest result (best),5 points-this is the lowest result (worst) Calculations were made using the Subjective assessment questionnaire on a 10-point scale. Which included questions from each questionnaire:Female Sexual Function Index (FSFI),ICIQ-SF (International Urinary Continence Index), PISQ-12 survey form, SF36 quality of life survey form. Questioning was conducted at the following time points: before laser treatment, one month after each laser treatment session, and 6 months after the last procedure.
Primary Change in vaginal dryness from baseline Efficacy was assessed by SF36 quality of life survey form means of the this is a non-specific questionnaire for assessing the patient's quality of life.When 1 point-is the highest result (best),5 points-this is the lowest result (worst). Questioning was conducted at the following time points: before laser treatment, one month after each laser treatment session, and 6 months after the last procedure.
Primary Change in frequency of involuntary urination (urinary incontinence) from baseline The effectiveness was assessed using ICIQ-SF (International Urine Retention Index), a subjective indicator of the severity of urine loss and quality of life in patients with urinary incontinence, using the format of questions on a 5-point Likert scale to assess the presence, severity and concomitant symptoms. This is a subjective indicator designed to assess the level, impact and suspected cause of urinary incontinence on the quality of life.5 points-the highest score of the result,0 point- the lowest score of the result.The total amount of points for answering the questions where 0 points - a slight degree of urinary incontinence,19 - 21 - very severe urinary incontinence. Questioning was conducted at the following time points: before laser treatment, one month after each laser treatment session, and 6 months after the last procedure.
Primary Change in frequency of involuntary urination during physical activities (stress urinary incontinence). Efficacy was assessed by means of the PISQ12 is a specific and reliable questionnaire consisting of three sections: behavioral and emotional characteristics, physical aspects and questions concerning the patient's relationship with a partner.Each item of the questionnaire contains five possible answers,which are evaluated in points.The result of the survey is expressed by the sum of points on all points.The maximum number of points is48,which is an indicator of the best sexual function. SF36 quality of life survey form means of the this is a non-specific questionnaire for assessing the patient's quality of life.When 1 point-is the highest result (best),5 points-this is the lowest result (worst) Questioning was conducted at the following time points: before laser treatment, one month after each laser treatment session, and 6 months after the last procedure.
Secondary Change in burning pain in the vagina from baseline Efficacy was assessed by means of the Female Sexual Function Index (FSFI)- a self-controlled questionnaire survey, including 19 items,allows you to evaluate the features of desire,arousal,arousal,orgasm,achieving sexual satisfaction,and the presence of dyspareunia.With the help of this questionnaire,it is possible to conduct a differential assessment of clinical manifestations of sexual disorders.5 points-the highest score of the result,1 point- the lowest score of the result. Questioning was conducted at the following time points: before laser treatment, one month after each laser treatment session, and 6 months after the last procedure.
See also
  Status Clinical Trial Phase
Recruiting NCT05812924 - A Novel Therapy for Breast Cancer Survivors With Genitourinary Syndrome of Menopause Phase 2
Completed NCT04535323 - Platelet Rich Plasma for the Treatment of Genitourinary Syndrome of Menopause in Patients With Stage 0-III Breast Cancer Phase 1
Completed NCT03331328 - MonaLisa Touch Randomized Double-Blind Placebo Controlled Study N/A
Recruiting NCT04746456 - Vulvovaginal Atrophy Questionnaire (VVAQ): Psychometric Validation of a Novel PROM
Withdrawn NCT04606550 - MonaLisa Laser Intervention for Post-Menopausal Breast Cancer Patients: A SHE CAN Study N/A
Completed NCT04705883 - Vaginal Prasterone In Vaginal Atrophy In Breast Cancer Survivors Phase 4
Recruiting NCT05953090 - VALOR: Vaginal Atrophy & Long-term Observation of Recovery N/A
Active, not recruiting NCT04619485 - Sexual and Vaginal Health in Breast Cancer Women Receiving Aromatase Inhibitors Before and After CO2 Laser Therapy N/A
Completed NCT04607798 - Multi-polar RF and PEMF for Treatment of Vulvovaginal Atrophy N/A
Recruiting NCT06124820 - RCT Comparing Intravaginal Laser Therapy to Sham in Post-menopausal Women With Recurrent Urinary Tract Infections N/A
Completed NCT05561972 - The Ultrasonographic Assessment of Efficacy of Injectable Hyaluronic Acid for Genitourinary Syndrome of Menopause N/A
Recruiting NCT05571527 - Comparison of Vaginal Hyaluronic Acid Treatment Over Autologous Platelet Rich Plasma Treatment for Genitourinary Syndrome of Menopause N/A
Recruiting NCT04677491 - Effects of Ospemifene on Brain Activation Patterns in Women With Sexual Interest-arousal Disorders Phase 4
Not yet recruiting NCT06425978 - Efficacy of the Use of Cellular Matrix/ A-CP-HA Kit Phase 4
Recruiting NCT05672901 - Silicone Gel vs. Estrogen Vaginal Cream for the Management of Genitourinary Syndrome of Menopause N/A
Recruiting NCT03782480 - Examining Effects of Intrarosa in Women With Genitourinary Syndrome of Menopause/Vulvovaginal Atrophy Phase 3
Recruiting NCT06028009 - PRP Injections for Genitourinary Syndrome of Menopause N/A
Not yet recruiting NCT06007027 - Vaginal CO2 Laser Therapy for Genitourinary Syndrome in Breast Cancer Survivors N/A
Terminated NCT03857893 - New Non-Hormonal Treatment by Radiofrequency for Vulvo-Vaginal Atrophy N/A
Completed NCT05782920 - Management of Cancer Therapy Related Vulvovaginal Atrophy N/A